ASH 2019 | ALL at ASH: four key updates
Marina Konopleva
• 8 Dec 2019
This year there was a strong set of acute lymphoblastic leukemia (ALL) data presented at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Here, Marina Konopleva, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses four key updates: the long-term data for hyper-CVAD plus ponatinib in the frontline for adult Ph+ ALL (abstract 238); Chinese data on the CD19/CD22 dual CAR-T therapy for R/R B-ALL (abstract 284); venetoclax with navitoclax in adult and pediatric R/R ALL (abstract 285); and insights from the whole genome profiling of adult B-other ALL on the UKALL14 trial.
